Drinking beetroot juice every day with at least 397 mg of nitrate can lower high blood pressure as much as common blood pressure pills do.
Claim Context
Daily dietary nitrate supplementation (≥397 mg) from beetroot juice significantly reduces systolic and diastolic blood pressure in hypertensive adults, with effect sizes comparable to first-line antihypertensive medications.
The claim uses 'significantly reduces' and 'comparable to', which imply a direct, measurable, and certain effect rather than a possibility or association. 'Significantly' is a statistical term often used in causal claims to assert a non-random, robust effect.
“An important study in 2014 tested the effects of daily doses of beetroot juice containing about 397 milligs of nitrate against a placebo in patients with high blood pressure. So, the study found that beetroot juice supplements did significantly reduce blood pressure by around eight points.”
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
Evidence from Studies
Supporting (3)
Community contributions welcome
Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study.
Plasma nitrate, dietary nitrate, blood pressure, and vascular health biomarkers: a GRADE-Assessed systematic review and dose-response meta-analysis of randomized controlled trials
Contradicting (2)
Community contributions welcome
Increased nitrate intake from beetroot juice over 4 weeks affects nitrate metabolism, but not vascular function or blood pressure in older adults with hypertension
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A double-blind, placebo-controlled RCT in adults diagnosed with hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg), where participants receive either daily beetroot juice providing ≥397 mg nitrate or a matched placebo juice for 4–8 weeks, with ambulatory blood pressure monitoring as the primary outcome, and first-line antihypertensive medication effect sizes used as a benchmark for comparison.
Double-blind, placebo-controlled RCT with parallel groups; population: adults with confirmed hypertension (n≥50 per group); intervention: beetroot juice providing ≥397 mg nitrate daily; comparator: nitrate-free placebo juice; outcome: change in 24-hour ambulatory systolic and diastolic blood pressure; duration: 6 weeks; primary endpoint: mean difference in systolic and diastolic BP vs placebo, with effect size compared to published meta-analyses of first-line antihypertensives.
A crossover RCT in hypertensive adults where each participant receives both beetroot juice (≥397 mg nitrate/day) and placebo in randomized order with a 2-week washout period between phases, measuring systolic and diastolic BP at the end of each phase to determine within-subject changes and compare effect size to standard antihypertensive medications.
Within-subject crossover RCT; population: adults with hypertension (n≥30); intervention: 4 weeks of beetroot juice (≥397 mg nitrate); comparator: 4 weeks of placebo juice; washout: 2 weeks; outcome: mean change in morning and evening home BP and 24-hour ambulatory BP; duration: 8–10 weeks total; primary endpoint: within-subject difference in BP between nitrate and placebo phases, with effect size benchmarked against first-line drug trials.
An RCT testing multiple doses of beetroot juice (e.g., 0 mg, 198 mg, 397 mg, 794 mg nitrate/day) in hypertensive adults over 4 weeks to determine if the blood pressure-lowering effect is dose-dependent and whether the ≥397 mg threshold produces an effect size matching first-line antihypertensives.
Parallel-group RCT with 4 arms; population: adults with hypertension (n≥20 per arm); interventions: daily beetroot juice providing 0, 198, 397, or 794 mg nitrate; comparator: placebo for 0 mg arm; outcome: change in systolic and diastolic BP via ambulatory monitoring; duration: 4 weeks; primary endpoint: linear or nonlinear dose-response relationship in BP reduction, with effect size of 397 mg group compared to published drug effect sizes.
A non-inferiority RCT comparing beetroot juice (≥397 mg nitrate/day) directly against a first-line antihypertensive medication (e.g., lisinopril or amlodipine) in hypertensive adults to determine if the juice reduces BP to a non-inferior degree.
Three-arm RCT: beetroot juice (≥397 mg nitrate/day), first-line antihypertensive (standard dose), and placebo; population: adults with stage 1–2 hypertension (n≥60 per arm); intervention duration: 8 weeks; outcome: change in systolic and diastolic BP; primary endpoint: non-inferiority margin set at 5 mmHg for systolic BP, with statistical test for non-inferiority of beetroot juice vs medication.
A prospective cohort study tracking hypertensive adults who self-select into daily beetroot juice consumption (≥397 mg nitrate) vs non-consumers over 12 months, measuring BP trends and comparing them to published medication effect sizes to assess real-world consistency.
Prospective cohort study; population: adults with hypertension (n≥200); exposure: daily beetroot juice intake ≥397 mg nitrate (verified by food diary and plasma nitrate); comparator: no beetroot juice intake; outcome: change in clinic and ambulatory BP at 3, 6, and 12 months; primary endpoint: mean BP reduction over time compared to baseline and to historical drug effect sizes; confounders adjusted via propensity scoring.